A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Apparatus and methods for concentrating platelet-rich plasma is described herein. One variation may generally comprise a tube having a length and defining a channel within and one or more ports located at a proximal end of the tube and in fluid communication with the channel. A plunger may slidably translatable within the channel while forming a seal against an inner surface of the channel and a float may have a pre-selected density and defining a concave interface surface, wherein the float is slidably contained within the channel such that the concave interface surface is in apposition to the one or more ports.

A method of collecting plasma includes receiving donor parameters at a controller of a plasma collection device electronically from a donor management system. The method includes storing a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The method includes setting the target volume for raw plasma and controlling the plasma collection device to operate draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and a second blood component comprising red blood cells and to return the second blood component to the donor. The controller operates the draw and return phases until a volume of raw plasma in the collection container equals the target volume of raw plasma.

A method of collecting plasma includes receiving donor parameters at a controller of a plasma collection device electronically from a donor management system. The method includes storing a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The method includes setting the target volume for raw plasma and controlling the plasma collection device to operate draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and a second blood component comprising red blood cells and to return the second blood component to the donor. The controller operates the draw and return phases until a volume of raw plasma in the collection container equals the target volume of raw plasma.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Embodiments herein relate to medical devices and methods for monitoring and/or treatment including the use of synthetic polymers exhibiting specific binding for compounds such as disease state markers or toxic substances. In an embodiment, a method of testing a patient for a disease state is included, the method can include withdrawing a fluid sample from the patient and contacting the fluid sample with an extracorporeal monitoring device. The extracorporeal monitoring device can include a microporous membrane. The microporous membrane can include a synthetic polymer, wherein the synthetic polymer exhibits binding specificity with a disease state marker. The method can further include evaluating the extracorporeal monitoring device for the presence of the disease state marker. Other embodiments are included herein.

Embodiments herein relate to medical devices and methods for monitoring and/or treatment including the use of synthetic polymers exhibiting specific binding for compounds such as disease state markers or toxic substances. In an embodiment, a method of testing a patient for a disease state is included, the method can include withdrawing a fluid sample from the patient and contacting the fluid sample with an extracorporeal monitoring device. The extracorporeal monitoring device can include a microporous membrane. The microporous membrane can include a synthetic polymer, wherein the synthetic polymer exhibits binding specificity with a disease state marker. The method can further include evaluating the extracorporeal monitoring device for the presence of the disease state marker. Other embodiments are included herein.

Blood in a separation chamber is separated into a red blood cell layer, a plasma constituent, and a mononuclear cell-containing layer. A portion of the plasma constituent exits the chamber via a plasma outlet, while a first portion of the red blood cell layer exits via a red blood cell outlet. A second portion of the red blood cell layer exits the chamber via the red blood cell outlet and is collected. At least a portion of the collected red blood cell layer may then be conveyed to the chamber via the red blood cell outlet to convey at least a portion of the mononuclear cell-containing layer out of the chamber via the plasma outlet for collection. A second portion of the plasma constituent may be conveyed out of the chamber via the plasma outlet to more fully collect the mononuclear cell-containing layer without the use of collected plasma.

Diffusion and infusion resistant implantable devices and methods for reducing pulsatile pressure are provided. The implantable device includes a balloon implantable within a blood vessel of a patient, e.g., the pulmonary artery. The balloon is injected with a fluid mixture comprising a constituent fluid(s) and a diffusion-resistant gas to provide optimal balloon volume and limit fluid diffusion throughout multiple cardiac cycles. The fluid mixture may be pressurized such that the balloon is transitionable between an expanded state and a collapsed state responsive to pressure fluctuations in the blood vessel.